Beneficial effects of donor-specific transfusion on renal allograft outcome
Beneficial effects of donor-specific transfusion on renal allograft outcome
复制标题
DOI：
10.1111/j.1399-0012.2010.01235.x
复制
发表时间：
2011-03-01
影响因子：
2.1
通讯作者：
Djukanovic, Ljubica
中科院分区：
文献类型：
--
作者：
Jovicic, Svetlana;Lezaic, Visnja;Djukanovic, Ljubica
引言：供体特异性输血（DST）被认为可以提高活体肾移植的移植物存活率。本研究的目的是确定DST对急性排斥反应（AR）的发生率，移植物功能和存活率在早期和晚期移植后期间在transfusion-naive.Methods的影响：三个患者组进行了比较：组1接受DST（n = 18），组2患者接受手术前没有输血（n = 13）和组3包括132随机输血患者。DST方案包括以两周的间隔输注新鲜的全血供体血液（3 × 150 mL），并伴随三天的硫唑嘌呤。所有患者均在第三次DST后一个月内进行移植。结果：DST组和多次输血组AR发生率明显低于第2组。与第2组相比，第1组和第3组患者的2年移植物功能明显更好。虽然类似的八年的患者和移植物存活率被发现在所有的组，延迟移植功能的患者有最长的移植物half-lifes.Conclusion：DST施加了显着的有益效果的发病率AR，DGF和移植物功能在移植后的第一年在输血-幼稚的患者接受标准的免疫抑制治疗。
Introduction:Donor-specific transfusion (DST) is claimed to improve graft survival in living kidney transplantation. The aim of this study was to determine the influence of DST on the incidence of acute rejection (AR), graft function and survival in the early and late post-transplantation period in transfusion-naive patients.Methods:Three patient groups were compared: group 1 received DST (n = 18), group 2 patients received no transfusion prior to surgery (n = 13) and group 3 consisted of 132 randomly transfused patients. The DST protocol consisted of infusion of fresh whole donor blood (3 x 150 mL) at two-wk intervals accompanied by three d of azathioprine. All patients were grafted within one month after the third DST. Triple drug immunosuppression based on cyclosporine A was given to all patients.Results:DST and polytransfused patients experienced significantly less AR compared with group 2 patients. Two-yr graft function was significantly better in patients in groups 1 and 3 compared with group 2. Although similar eight-yr patient and graft survival was found in all the groups, delayed graft function patients had the longest graft half-life.Conclusion:DST imposes a significant beneficial effect on the incidence of AR, DGF and graft function during the first post-transplantation year in transfusion-naive patients receiving standard immunosuppression therapy.